Credits: Canva
An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.
One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.
Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.
The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.
The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.
Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”
The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.
Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.
The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.
Credit: Instagram
Marketa Vondrousova, the 2023 Wimbledon singles champion, has been banned from professional sport for four years after refusing an anti-doping test.
According to an independent tribunal, the 26-year-old provided “no compelling justification” for declining to provide a sample after being notified at her home by a doping control officer in December.
“We recognize that this is a significant ban. And the reason for that is that you can’t have an anti-doping system where a player is in a better place by refusing to take a test than they would be by taking the test and testing positive,” said Karen Moorhouse, chief executive of the International Tennis Integrity Agency (ITIA).
“That feeds into the structure of the doping rules that provides for a starting point of a four-year ban for refusing to take a test, the same as a starting point for testing positive,” she added.
The Czech player said in April that she feared for her safety when the officer called and claimed the officer had failed to follow protocol.
Vondrousova reached the French Open final in 2019, won an Olympic silver medal in 2021, and achieved a career-high ranking of No. 6.
“I have never doped, I have never had a positive test. Throughout my entire career, I have undergone countless anti-doping controls and have always stepped onto the court with a clear conscience. I cannot say what comes next. For the first time in my life, I do not have a plan,” she said in a statement.
She is suspended from all professional events until June 21, 2030, but has the right to appeal the decision to the Court of Arbitration for Sport (CAS).
According to Vondrousova, the doping control officer did not adhere to the rules by approaching her outside the hour she had designated under the whereabouts rules. During the hearing, Vondrousova said stress and poor mental health had affected her decision-making, in addition to her safety concerns.
Also read: Why Sleeping Pill Addiction Is Common Among Football Players
Doping control (testing) is one tool that Anti-Doping Organizations (ADOs) use to level the playing field and protect clean sport.
As per the World Anti-Doping Agency (WADA), athletes playing at the national or international level can be subject to doping control and can be tested anytime or anywhere.
Credit: iStock
Amid a red alert for a severe heatwave in the UK, the Met Office has also warned of a "pollen bomb" that could significantly affect people with hay fever.
The forecaster said there is no evidence that pollen levels are worse this year, but symptoms may feel more severe due to a combination of high pollen counts and exposure to multiple pollen types.
A 2026 Lancet Countdown in Europe study found that climate change is altering the flowering seasons of plants that release allergenic pollen.
“The combination of the fairly breezy and dry weather is going to bring a lot of pollen into the air this week and for the coming weeks,” Alastair Culham, Professor of Botany at the University of Reading, told The Independent.
“We've seen quite a mixed year so far, a very warm, dry spring which brought pollen on early, and then a series of wet weather which has allowed the grasses to grow exceptionally well. Now the weather has warmed and dried, those grasses are going into flower and the level of pollen from grass is phenomenally high,” he added.
Also read: UK Issues Red Heat-Health Alert: How to Protect Yourself From Extreme Heat
Rising temperatures, expected to exceed 30°C on several days this week, are causing trees and grasses to release large amounts of pollen into the air.
“Hay fever symptoms usually appear when the pollen count, which is a measure of the number of grains of pollen in one cubic meter of air, exceeds 50,” the Met Office said.
The agency noted that weather conditions influence how much pollen is released and spread. Humid and windy conditions help pollen travel, while rain can clear it from the air. On sunny days, pollen levels are typically highest in the early evening.
Read To Know: No Women Aged 20-24 Died of Cervical Cancer in England Over Five Years, Thanks to HPV Vaccine
The Met Office has warned that grass pollen will remain at high levels across England and Wales, with Yorkshire, the Midlands and the North West expected to experience very high counts.

Pollen levels are forecast to be very high across England on June 24, with temperatures reaching around 38°C in some areas.
Northern Ireland and Scotland are also expected to experience medium to high pollen levels throughout the week.
Read More: WHO Sounds Alarm on Europe's Extreme Heat: Here's How Hot It Could Get Across Countries
Hay fever is a common allergy that causes sneezing, coughing and itchy eyes.
According to Allergy UK, one in four adults and one in eight children suffer from allergic rhinitis, the medical term for hay fever. Research suggests the number of sufferers is increasing each year.
The Lancet study found that hay fever sufferers now experience symptoms for up to two weeks longer than they did in the 1990s due to climate change.
According to the UK NHS, hay fever can last for weeks or months, unlike a cold, which usually resolves within one to two weeks. While there is no cure, symptoms can be managed when pollen levels are high.
Credit: https://johnleeindia.com/
More than 11,000 bottles of the blood pressure medication Chlorthalidone, manufactured in India, have been recalled in the United States, according to the Food and Drug Administration (FDA). This is the second India-made blood pressure drug to be recalled in over a month.
Mumbai-based manufacturer Inventia Healthcare Limited recalled the prescription-only Chlorthalidone Tablets USP, 25 mg on June 5 due to "failed dissolution specifications." This means that the tablets may not break down correctly in the body. The drug is sold under several brand names, including Thalitone and Hygroton, and is distributed in America by New Jersey-based Rising Pharma Holdings.
Also read: Robert F. Kennedy Jr. Launches Reforms To Speed Up Early Drug Research In US
Chlorthalidone is a diuretic, or "water pill," prescribed to treat high blood pressure and fluid retention associated with conditions such as congestive heart failure, kidney disease, and liver disease.
It works by helping the kidneys eliminate excess water and salt through urine.
The FDA has not yet classified the recall or detailed the potential health consequences for patients.
Dissolution refers to the process by which a tablet breaks down and releases its active ingredient into the body after it is taken.
A dissolution failure means that, during regulatory testing, the tablets did not dissolve as required. As a result, the active ingredient may not be released properly, potentially reducing the amount of medicine that reaches the bloodstream and works as intended, according to Cardiovascular Business..
Dissolution problems can arise from several factors, including poor formulation design, manufacturing process issues, low-quality raw materials, or stability issues that affect the product over time.
Also read: US FDA Panel Recommends First-Ever mRNA Flu Shot For Older Adults: All About The Moderna Vaccine
According to the FDA, 11,460 bottles of Chlorthalidone are included in the recall and carry an expiration date of April 2027.
The recall affects:
Read More: 4 Indian States Roll Out IV Iron Therapy To Curb Anemia In Pregnant Women: How It Works
The recall follows another FDA recall announced on May 5 involving Amlodipine and Olmesartan Medoxomil Tablets (5 mg/40 mg), another prescription blood pressure medication.
A total of 15,696 bottles were recalled due to "failed dissolution specifications: Olmesartan Medoxomil content below specifications."
The medication was also manufactured by Alkem Laboratories Ltd. in India and distributed by Ascend Laboratories, LLC, Parsippany, New Jersey. The recalled bottles carry an expiration date of October 31, 2027.
Both recalls were issued nationwide.
The latest recall follows a separate large-scale blood pressure medication recall in October, when manufacturers recalled more than 500,000 bottles of Prazosin Hydrochloride due to contamination concerns.
That recall involved potential contamination with unsafe levels of a cancer-causing chemical, prompting the manufacturer to advise patients to consult their physicians or pharmacists.
© 2024 Bennett, Coleman & Company Limited